- Consumer Products
- Latest 61.58
- Currency US$
- Change 0.33
- Percent Change 0.539 %
- Volume 25,795
- Thu Apr 17, 2014 10:23 AM EDT NASDAQ data delayed 15 minutes.
12 months ended Jan 31, 2014.
Trailing 12 month results shown above.
All data is in U.S. dollars.
|Earnings||Feb 20||$0.49||Jun 4||$0.55|
12 months ended Apr 17, 2014.
A look at major corporate events and financial announcements that are coming up.
About the Company
Cyberonics, Inc. was founded to design, develop and market medical devices for the treatment of epilepsy and other debilitating neurological disorders using a therapy, vagus nerve stimulation. The company's initial target market is epilepsy, the world's second most prevalent neurological disorder, which is characterized by seizures. Vagus nerve stimulation with the Cyberonics NCP System was approved for use as an adjunctive therapy in reducing the frequency of seizures in adults and adolescents with medically refractory partial onset seizures. (PRESS RELEASE)